Cited by 710Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical TreatmentsGenetic factors in colorectal cancer

The DOI matches its Crossref record, with a small difference in title or year; 24 of the 24 references it cites were found in a registry or an index.

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

Open access

Tejpar, Sabine, Stintzing, Sebastian, Ciardiello, Fortunato, Tabernero, Josep, Van Cutsem, Eric, Beier, Frank, Esser, Regina, Lenz, Heinz-Josef, Heinemann, Volker·2017·JAMA Oncology

DOI 10.1001/jamaoncol.2016.3797PMC PMC7505121

Open this paper in CoChat — free account

Abstract

IMPORTANCE: Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors arising from different regions of the colon are clinically and molecularly distinct. OBJECTIVE: To examine the prognostic and predictive value of primary tumor location in patients with RAS wild-type (wt) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) trial and FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment For Patients With Metastatic Colorectal Cancer (FIRE-3) trial. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective analysis patients with RAS wt metastatic colorectal cancer from the CRYSTAL and FIRE-3 trials were classified as having left-sided or right-sided mCRC, defined, respectively, as patients whose tumors originated in the splenic flexure, descending colon, sigmoid colon, or rectum vs appendix, cecum, ascending colon, hepatic flexure, or transverse colon. MAIN OUTCOMES AND MEASURES: Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were assessed according to tumor location and treatment arm. RESULTS: In the RAS wt populations of the CRYSTAL and FIRE-3 trials, patients with left-sided tumors (n = 142 and n = 157, respectively) had markedly superior PFS, OS, and ORR compared with patients with right-sided tumors (n = 33 and n = 38, respectively). Among CRYSTAL and FIRE-3 study patients with RAS wt left-sided tumors, FOLFIRI plus cetuximab significantly improved OS relative to the respective comparators (FOLFIRI and FOLFIRI plus bevacizumab); in contrast, in RAS wt patients with poor-prognosis right-sided tumors, limited efficacy benefits were observed upon the addition of cetuximab to FOLFIRI in CRYSTAL, and comparable outcomes were observed between the FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab arms of FIRE-3. A significant interaction was observed between primary tumor location and treatment for OS (CRYSTAL: hazard ratio [HR], 1.95; 95% CI, 1.09-3.48 and FIRE-3: HR, 0.40; 95% CI, 0.23-0.70) within the RAS wt populations of both studies in multivariable models that also included sex, prior adjuvant therapy, and BRAF mutational status. CONCLUSIONS AND RELEVANCE: In the RAS wt populations of CRYSTAL and FIRE-3, patients with left-sided tumors had a markedly better prognosis than those with right-sided tumors. First-line FOLFIRI plus cetuximab clearly benefitted patients with left-sided tumors (vs FOLFIRI or FOLFIRI plus bevacizumab, respectively), whereas patients with right-sided tumors derived limited benefit from standard treatments. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: CRYSTAL, NCT00154102, and FIRE-3, NCT00433927.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2016.3797

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citation
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citation
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Van Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citation
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial
Heinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Self-citation
Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer
Van Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citation
The Pan-ErbB Negative Regulator Lrig1 Is an Intestinal Stem Cell Marker that Functions as a Tumor Suppressor
Powell, A. E., Wang, Y., Li, Y., Poulin, E. J., Means, A. L., Washington, M. K., Higginbotham, J. N., Juchheim, A., Prasad, N., Levy, S. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.042 · Cited by 694
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D’Ario, G., Narzo, A. F. D., Soneson, C., Budínská, E., Popovici, V. C., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646
Self-citation
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., Maus, M. K. H., Antoniotti, C., Langer, C., Scherer, S. J., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju427 · Cited by 477
Self-citation
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
Brule, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R. P. W., Tebbutt, N. C., Underhill, C. R., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 335

Flagged first, then by citations

Show all 24 references

Sorted by citations

Items 401–500 of 710

Anatomical resection improves relapse-free survival in colorectal liver metastases in patients with KRAS/NRAS/BRAF mutations or right-sided colon cancer: a retrospective cohort study
Chang, W., Chen, Y., Zhou, S., Ren, L., Xu, Y., Zhu, D., Tang, W., Ye, Q., Wang, X., Fan, J., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000562 · Cited by 6
Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials
Vasconcelos, J. P. S., Chen, N., Titmuss, E., Tu, D., Brule, S. Y., Goodwin, R. A., Jonker, D. J., Price, T. J., Zalcberg, J. R., Moore, M. J., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3275 · Cited by 6
Investigation of tumor-tumor interactions in a double human cervical carcinoma xenograft model in nude mice
Mertens, B., Nogueira, T. C. D. A., Topalis, D., Stránská, R., Snoeck, R., & Andreï, G. (2018) · Oncotarget · doi:10.18632/oncotarget.25140 · Cited by 6
Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer
Iwamoto, S., Maeda, H., Hazama, S., Oba, K., Okayama, N., Suehiro, Y., Yamasaki, T., Suzuki, N., Nagano, H., Sakamoto, J., et al. (2018) · Journal of Cancer · doi:10.7150/jca.26840 · Cited by 6
Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer
Baek, S. K., Lee, K. T., Bae, S. B., & Lee, S. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.071 · Cited by 6
Association between polymorphisms in EGFR and tumor response during cetuximab and oxaliplatin‑based combination therapy in metastatic colorectal cancer: Analysis of data from two clinical trials
Maeda, H., Hazama, S., Iwamoto, S., Oba, K., Tsunedomi, R., Okayama, N., Suehiro, Y., Yamasaki, T., Nakagami, Y., Suzuki, N., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10787 · Cited by 6
A qualitative transcriptional signature for predicting microsatellite instability status of right-sided Colon Cancer
Fu, Y., Qi, L., Guo, W., Jin, L., Song, K., You, T., Zhang, S., Gu, Y., Zhao, W., & Guo, Z. (2019) · BMC Genomics · doi:10.1186/s12864-019-6129-8 · Cited by 6
FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival
Jacome, A. A. D. A., Kee, B. K., Fogelman, D. R., Dasari, A. N., Shureiqi, I., Raghav, K. P. S., Morris, V. K., Johnson, B., Overman, M. J., Wolff, R. A., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.05.010 · Cited by 6
An appraisal of emerging second line therapies for metastatic colorectal cancer
Smolenschi, C., Perret, A., Dall'Armellina, F., Boige, V., Malka, D., Hollebecque, A., & Ducreux, M. P. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1840975 · Cited by 6
Treatment sequencing of metastatic colorectal cancer based on primary tumor location
Temraz, S. N., Mukherji, D., Nassar, F. J., Moukalled, N. M., & Shamseddine, A. I. (2021) · Seminars in Oncology · doi:10.1053/j.seminoncol.2021.05.001 · Cited by 5
Genomic Analysis Reveals Heterogeneity Between Lesions in Synchronous Primary Right-Sided and Left-Sided Colon Cancer
Hu, H., Zhang, Q., Huang, R., Gao, Z., Yuan, Z., Tang, Q., Gao, F., Wang, M., Zhang, W., Ma, T., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.689466 · Cited by 6
Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers
Yu, I. S., Al-Hashami, Z. S., Chapani, P., Speers, C. H., Davies, J. M., Lim, H. J., Renouf, D. J., Gill, S., Stuart, H., & Loree, J. M. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.11.006 · Cited by 6
Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence
Rico, G. T., Townsend, A. R., Broadbridge, V. T., & Price, T. J. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0439-9 · Cited by 6
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer
Gelsomino, F., Spallanzani, A., Orsi, G., Caputo, F., Santini, C., & Cascinu, S. (2018) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2018.10.001 · Cited by 6
Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis
Fiala, O., Veškrňová, V., Chloupková, R., Poprach, A., Kišš, I., Kopečková, K., Dušek, L., Slavicek, L., Kohoutek, M., Fínek, J., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0597-7 · Cited by 6
Effective chemotherapy and targeted therapy supplemented with stereotactic radiotherapy of a patient with metastatic colon cancer following renal transplantation: a case report
Bellyei, S., Boronkai, Á., Pozsgai, É., Fodor, D., & Mangel, L. (2021) · Journal of Medical Case Reports · doi:10.1186/s13256-021-02702-y · Cited by 6
State of the art of the molecular hyperselection to guide treatment with anti-EGFR antibodies in RAS WT mCRC: implications for clinical practice and future perspectives
Alfonso, P. G., Valladares‐Ayerbes, M., Martín, A. J. M., Herrero, R. M., Muñoz, E. G., & Prat-Llorens, G. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2477192 · Cited by 5
Impact of Sidedness of Colon Cancer on Epidemiological, Clinical Presentation, Surgical, Pathological, and Oncologic Outcomes
Filho, O. D. M., Martins, B. A. A., Silva, A. A. D. M., dos Santos, A. C. N., de Almeida, R. M., & de Sousa, J. B. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14121153 · Cited by 5
Anlotinib in combination with metronomic chemotherapy in HER2-negative metastatic breast cancer: an observational and retrospective study
Liu, J., Zhang, J., Li, H., Song, G., Di, L., Jiang, H., Yan, Y., Wang, H., Wang, J., Liu, X., et al. (2025) · BMC Cancer · doi:10.1186/s12885-024-13403-2 · Cited by 5
The Clinical Significance of Microsatellite Instability in Patients with Right-sided Colorectal Cancer
Han, S. A., Kim, J. H., Choi, J. H., Lee, D. H., Jung, K., Kim, S. E., Moon, W., Park, M. I., & Park, S. J. (2019) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2019.73.3.159 · Cited by 5
The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer
Beypınar, İ., Demir, H., Araz, M., Baykara, M., & Aykan, N. F. (2020) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-020-00542-5 · Cited by 4
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and Rectum
Ito, T., Takashima, A., Yamazaki, K., Yukami, H., Uetake, H., Tsuda, M., Suto, T., Moriwaki, T., Sugimoto, N., Ojima, H., et al. (2022) · International Journal of Clinical Oncology · doi:10.1007/s10147-022-02208-7 · Cited by 5
Development and validation of a new stage-specific nomogram model for predicting cancer-specific survival in patients in different stages of colon cancer: A SEER population-based study and external validation
Hu, C., Shi, F., Zhang, Z., Zhang, L., Liu, R., Sun, X., Zheng, L., & She, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1024467 · Cited by 5
COLORECTAL CANCER: HISTOPATHOLOGICAL PROFILE AND PREVALENCE OF DNA REPAIR SYSTEM DEFICIENCY IN PATIENTS SUBMITTED TO SURGICAL TREATMENT IN A UNIVERSITY HOSPITAL
de Oliveira, J. W., de Moraes, R. A., Mehanna, S. H., & Linhares, J. C. (2023) · ABCD Arquivos Brasileiros de Cirurgia Digestiva (São Paulo) · doi:10.1590/0102-672020230053e1771 · Cited by 5
High CIB1 expression in colorectal cancer liver metastases correlates with worse survival and the replacement histopathological growth pattern
Fan, S., Fleischer, J. R., Dokshokova, L., Böhme, L. S., Haas, G., Schmitt, A. M., Gätje, F. B., Rosen, L.-A., Bohnenberger, H., Ghadimi, M. B., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200828 · Cited by 5
FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer
Geredeli, Ç., & Yaşar, N. (2018) · World Journal of Surgical Oncology · doi:10.1186/s12957-018-1359-9 · Cited by 5
Primary tumor location affects recurrence-free survival for patients with colorectal liver metastases after hepatectomy: a propensity score matching analysis
Zhang, Y., Wang, Y., Yuan, Y., Qiu, J., Qiu, Y., He, W. A., Zheng, Y., Wang, Z., Lu, Z., Lu, Z., et al. (2020) · World Journal of Surgical Oncology · doi:10.1186/s12957-020-01875-y · Cited by 5
The impact of molecular profile on the lymphatic spread pattern in stage III colon cancer
Song, J., Kataoka, K., Yamada, T., Shiozawa, M., Sonoyama, T., Beppu, N., Ueda, K., Kuriyama, S., Kanazawa, A., Ikeda, M., et al. (2021) · Cancer Science · doi:10.1111/cas.14819 · Cited by 5
Shared decision-making and patient decision aids in choosing first-line targeted therapy for metastatic colorectal cancer in Taiwan
Wu, C., Wang, J., Chang, M., Chen, Y., Wang, Y.-C., Lee, M.-H., Lin, C.-Y. E., Su, Y., Lin, P., & Hsu, C. (2021) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552211020806 · Cited by 5
Immune Checkpoint Blockade in Lower Gastrointestinal Cancers: A Systematic Review
Wilson, K., Flood, M. P., Oh, D., Calvin, N., Michael, M., Ramsay, R. G., & Heriot, A. G. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10192-x · Cited by 5
Einfluss der Molekularpathologie auf die onkologische Chirurgie des kolorektalen Karzinoms
Nöpel‐Dünnebacke, S., Conradi, L., Reinacher‐Schick, A., & Ghadimi, M. B. (2021) · Der Chirurg · doi:10.1007/s00104-021-01486-7 · Cited by 5
Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
Alig, A. H. S., Heinemann, V., Geißler, M., von Weikersthal, L. F., Decker, T. W., Heinrich, K., Held, S., Weiss, L., Fischer, L. E., Moosmann, N., et al. (2022) · Cancers · doi:10.3390/cancers14030526 · Cited by 5
Self-citation
Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial
de Rauglaudre, B., Sibertin-Blanc, C., Fabre, A. J., Malicot, K. L., Bennouna, J., Ghiringhelli, F., Taı̈eb, J., Boige, V., Bouché, O., Chatellier, T., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221141307 · Cited by 5
Pharmacoeconomic evaluation of the use of targeted therapy and chemotherapy in the first- and second-line therapies for metastatic colorectal cancer
Tryakin, A. A., & Balunov, P. A. (2018) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2018-19-50-55 · Cited by 5
Phase II APEC trial: The impact of primary tumor side on outcomes of first‐line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild‐type metastatic colorectal cancer
Price, T. J., Shen, L., Ma, B. B. Y., Esser, R., Chen, W., Gibbs, P., Lim, R. S. C., & Cheng, A. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13154 · Cited by 5
Self-citation
Impact of Primary Tumor Laterality on Adjuvant Hepatic Artery Infusion Pump Chemotherapy in Resected Colon Cancer Liver Metastases: Analysis of 487 Patients
Gholami, S., Stewart, S., Kemeny, N. E., Gönen, M., Koerkamp, B. G., Cercek, A., Kingham, T. P., Balachandran, V. P., Allen, P. J., DeMatteo, R. P., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09369-7 · Cited by 5
Prognostic value of the combination of primary tumor location and RAS mutational status on patients with colorectal liver metastasis undergoing hepatectomy
Yan, X., Wang, K., Bao, Q., Wang, H., Jin, K., Su, Y., & Xing, B. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.26816 · Cited by 5
Treatment of Rectal Cancer in Older Adults
Sheikh, A. R., Yameen, H., & Hartshorn, K. L. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0746-2 · Cited by 5
Comparative effectiveness of bevacizumab, cetuximab, and panitumumab for improving outcomes in metastatic colorectal cancer: a propensity overlap weighting analysis
Su, Y., Su, C., Lee, P., & Wu, C. (2025) · Annals of Coloproctology · doi:10.3393/ac.2025.00059.0008 · Cited by 4
EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance
Abbas, N., Mourad, M., Smaily, H., Al Mahmasani, L., & Shamseddine, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073265 · Cited by 4
Localized colorectal cancer database integrating 4 randomized controlled trials; (JCOG2310A)
Kataoka, K., Ouchi, A., Suwa, Y., Hirano, H., Yamaguchi, T., Takamizawa, Y., Hanaoka, M., Iguchi, K., Boku, S., Nagata, K., et al. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108354 · Cited by 4
The survival outcome differs between left-sided colon cancer and middle/low rectal cancer after colorectal hepatic metastasectomy
Yang, J.-H., Lin, W.-L., Chen, W., Jiang, J., Yang, S., Wang, H., Chang, S., Lan, Y., Lin, C., Lin, H., et al. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.05.020 · Cited by 4
Comparative efficacy of cetuximab combined with FOLFOX or CAPEOX in first-line treatment of RAS/BRAF wild-type metastatic colorectal cancer: a multicenter case-control study
Xu, C., Ren, J., Liu, C., Gai, Y., Cheng, X., Wang, Y., & Wang, G. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001697 · Cited by 4
Should Anti-EGFR Agents Be Used in Right-Sided RAS Wild-type Advanced Colorectal Cancer?
Triest, L., Debeuckelaere, C., Vandamme, T., van den Heuvel, B., den Brande, J. V., Papadimitriou, K., Rasschaert, M. A., Prenen, H., & Peeters, M. (2019) · Current Colorectal Cancer Reports · doi:10.1007/s11888-019-00439-x · Cited by 4
Treatment Trends and Clinical Outcomes of Left-Sided RAS/RAF Wild-Type Metastatic Colorectal Cancer in the United States
Nevala-Plagemann, C., Iyengar, S. K., Trunk, A. D., Pappas, L. M., Haaland, B. A., & Garrido‐Laguna, I. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7079 · Cited by 4
Management and pharmacotherapy of pediatric colorectal carcinoma: a review
Bergamaschi, L., Chiaravalli, S., Signoroni, S., Bartolomeo, M. D., & Ferrari, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2230123 · Cited by 4
Real-World Study to Assess Patterns of Treatment Practices and Clinical Outcomes in Metastatic Colorectal Cancer Patients with RAS Wild-Type Left-Sided Tumours in Canada
Boyne, D. J., Ngan, E., Carbonell, C., Wani, R. J., Morris, C. C., Martinez, D. J., & Cheung, W. Y. (2023) · Current Oncology · doi:10.3390/curroncol30090596 · Cited by 4
Selecting Optimal First-Line Treatment for Microsatellite Stable and Non-Mutated RAS/BRAF Metastatic Colorectal Cancer
Emiloju, O. E., Zhu, M., Xie, H., Jin, Z., Sinicrope, F. A., & Hubbard, J. M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01142-8 · Cited by 4
Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia
Radić, J., Nikolić, I., Kolarov-Bjelobrk, I., Vasiljević, T., Djurić, A., Vidović, V., & Kožik, B. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14080879 · Cited by 4
Outcomes of stage IV patients with colorectal cancer treated in a single institution: What is the key to the long-term survival?
Mukai, T., Uehara, K., Aiba, T., Nakamura, H., Ebata, T., & Nagino, M. (2018) · Journal of the Anus Rectum and Colon · doi:10.23922/jarc.2017-021 · Cited by 4
Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates
Koch, C., Schmidt, N., Winkelmann, R., Eichler, K., Pession, U., Bechstein, W. O., Zeuzem, S., Waidmann, O., & Trojan, J. (2018) · Digestion · doi:10.1159/000490888 · Cited by 4
A Routine Laboratory Data–Based Model for Predicting Recurrence After Curative Resection of Stage II Colorectal Cancer
Ye, Z., Wang, C., Guo, L., Palazzo, J., Han, Z., Lai, Y., Jiang, J., Posey, J. A., Mallick, A. B., Li, B., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.7048 · Cited by 4
The prognostic relevance of primary tumor sidedness to surgical treatment for recurrent colon cancer
Uchino, T., Ouchi, A., Komori, K., Kinoshita, T., Oshiro, T., Sano, T., & Shimizu, Y. (2020) · Surgery Today · doi:10.1007/s00595-020-02060-0 · Cited by 4
Survival Benefit of Palliative Primary Tumor Resection Based on Tumor Location in Patients with Metastatic Colorectal Cancer: A Single-center Retrospective Study
Kim, J. H., Jin, S., Jeon, M. J., Jung, H. Y., Byun, S., Jung, K., Kim, S. E., Moon, W., Park, M. I., & Park, S. J. (2020) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2020.76.1.17 · Cited by 4
Racial disparity in survival of patients diagnosed with early-onset colorectal cancer
Wallace, K., Li, H., Paulos, C. M., Lewin, D., & Alekseyenko, A. V. (2020) · Colorectal Cancer · doi:10.2217/crc-2020-0015 · Cited by 4
Impact of Biomarkers and Primary Tumor Location on the Metastatic Colorectal Cancer First-Line Treatment Landscape in Five European Countries
Kafatos, G., Banks, V., Burdon, P., Neasham, D., Lowe, K. A., Anger, C., Manuguid, F., & Trojan, J. (2021) · Future Oncology · doi:10.2217/fon-2020-0976 · Cited by 4
Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Benavides, M., Gómez‐España, A., Alfonso, P. G., González, C. G., Viéitez, J. M., Rivera, F., Safont, M. J., Abad, A., Sastre, J., Valladares‐Ayerbes, M., et al. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.11.122 · Cited by 4
Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia
Elsamany, S. A., Elsisi, G. H., Hassanin, F., Saleh, K., & Tashkandi, E. M. (2021) · Value in Health Regional Issues · doi:10.1016/j.vhri.2021.07.001 · Cited by 4
Long-term Survival Update and Extended RAS Mutational Analysis of the CAIRO2 Trial: Addition of Cetuximab to CAPOX/Bevacizumab in Metastatic Colorectal Cancer
ten Hoorn, S., Mol, L., Sommeijer, D. W., Nijman, L. E., van den Bosch, T., de Back, T. R., Ylstra, B., van Dijk, E., van Noesel, C. J. M., Reinten, R. J. A., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.006 · Cited by 4
Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required
Eng, C., & Rogers, J. E. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1561866 · Cited by 4
An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients
Guo, W., Fu, Y., Jin, L., Song, K., Yu, R., Li, T., Qi, L., Gu, Y., Zhao, W., & Guo, Z. (2019) · Journal of Cancer · doi:10.7150/jca.34363 · Cited by 4
The Budget Impact of Monoclonal Antibodies Used to Treat Metastatic Colorectal Cancer in Minas Gerais, Brazil
da Silva, W. C., Godman, B., Acúrcio, F. D. A., Cherchiglia, M. L., Martin, A. P., Maruszczyk, K., Izidoro, J. B., Portella, M. A. M., Lana, A. P., Neto, O. H. C., et al. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-020-00626-0 · Cited by 4
Cetuximab Therapy and RAS and BRAF Genotype
Dean, L., & Kane, M. S. (2020) · Europe PMC (PubMed Central) · Cited by 4
Another Chapter of the Right Versus Left Story: Is Primary Tumor Location a Prognostic Feature in RAS Mutant Metastatic Colorectal Cancer?
Loupakis, F., Schirripa, M., Intini, R., Bergamo, F., Bertorelle, R., Fassan, M., Dadduzio, V., Merigliano, S., Pilati, P., Urso, E. D. L., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0180 · Cited by 4
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
Köhne, C., Karthaus, M., Mineur, L., Thaler, J., den Eynde, M. V., Gallego-Plazas, J., Koukakis, R., Berkhout, M., & Hofheinz, R. (2019) · Drugs in R&D · doi:10.1007/s40268-019-0278-8 · Cited by 4
Management of metastatic colorectal cancer in patients ≥70 years - a single center experience
Huemer, F., Dunkl, C., Rinnerthaler, G., Schlick, K., Heregger, R., Emmanuel, K., Neureiter, D., Klieser, E., Deutschmann, M., Roeder, F., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1222951 · Cited by 4
GAME-SCORE predicts pathological and radiological response to chemotherapy in patients with colorectal liver metastases
Russolillo, N., Zingaretti, C. C., Langella, S., Fontana, A. P., Tesoriere, R. L., & Ferrero, A. (2024) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2024.108529 · Cited by 3
Anlotinib plus sintilimab as first-line treatment for patients with advanced colorectal cancer (APICAL-CRC): an open-label, single-arm, phase II trial
Wang, Z., Qin, B., Ye, C.-Y., Wang, M., Yuan, L., Yao, H., Jiao, X., Liu, K., Zhou, W., Qin, W., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02383-9 · Cited by 3
Harnessing epigenetics: Genome-wide DNA methylation assay for colorectal cancer therapy
Ishioka, C. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.103062 · Cited by 4
Molecular Targeting of EGFR, BRAF, and HER2 Signaling in Colorectal Cancer: Contemporary Advances with Panitumumab, Encorafenib, and Tucatinib
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062387 · Cited by 4
Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis
Chen, D., Zhang, X., Gao, G., Shen, L., Xie, J., Qian, X., & Wang, H. (2018) · World Journal of Surgical Oncology · doi:10.1186/s12957-018-1502-7 · Cited by 3
Primary Tumor-Related Complications Among Patients With Unresectable Stage IV Colorectal Cancer in the Era of Targeted Therapy: A Competing Risk Regression Analysis
Tanabe, T., Shida, D., Boku, N., Yoshida, T., Tsukamoto, S., Takashima, A., & Kanemitsu, Y. (2021) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002010 · Cited by 3
Tumors of the Small Intestine, Colon, and Rectum
Signoroni, S., Bartolomeo, M. D., & Ferrari, A. (2022) · Pediatric oncology · doi:10.1007/978-3-030-92071-5_25 · Cited by 3
Armamentarium in Drug Delivery for Colorectal Cancer
Ali, A., Akhtar, J., Ahmad, U., Basheer, A. S., Jaiswal, N., & Jahan, A. (2022) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2022039241 · Cited by 4
Clinicopathological Profiles Associated with Discordant RAS Mutational Status between Liquid and Tissue Biopsies in a Real-World Cohort of Metastatic Colorectal Cancer
Brozos-Vázquez, E., Lago‐Lestón, R. M., Covela, M., Gómez, J. D. L. C., Montés, A. F., Candamio, S., Vidal, Y., Vázquez, F., Abalo, A., López, R., et al. (2023) · Cancers · doi:10.3390/cancers15143578 · Cited by 3
Overall Survival, BRAF, RAS, and MSI Status in Patients Who Underwent Cetuximab After Refractory Chemotherapy for Metastatic Colorectal Cancer
Santos, F. A., Reis, R. M., Barroti, L. D. C., Pereira, A. A. L., Matsushita, M., de Carvalho, A. C., Datorre, J. G., Berardinelli, G. N., & Araújo, R. L. C. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-023-00964-x · Cited by 3
A population-based analysis on the incidence of metachronous colon cancer after endoscopic resection of advanced adenomas with high-grade dysplasia: does location matter?
Boatman, S. M., Kohn, J. F., Mott, S. L., Gaertner, W. B., Madoff, R. D., Melton, G. B., Shaukat, A., Hassan, I., & Goffredo, P. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.02.024 · Cited by 3
Qualitative Transcriptional Signature for Predicting the Pathological Response of Colorectal Cancer to FOLFIRI Therapy
He, J., Wang, M., Wu, D., Fu, H., & Shen, X. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312771 · Cited by 3
Does the Addition of Biologic Agents to Chemotherapy in Patients with Unresectable Colorectal Cancer Metastases Result in a Higher Proportion of Patients Undergoing Resection? A Systematic Review and Meta-analysis
Bogach, J., Levine, O. H., Parpia, S., Valencia, M., Ruo, L., & Serrano, P. E. (2017) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-017-3640-6 · Cited by 3
Molecular stratification of colorectal cancer populations and its use in directing precision medicine
Yang, M., & Yeatman, T. J. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1362316 · Cited by 3
Peritumoral activated hepatic stellate cells are associated with hepatic recurrence for resectable colorectal adenocarcinoma liver metastasis following resection
Deng, L., Li, T., Liao, Y., Liu, S., Xie, Z., Huang, Z., Dai, H., Li, J., & Lei, X. (2020) · Oncology Letters · doi:10.3892/ol.2020.12150 · Cited by 3
Retracted
The conversion of RAS status in metastatic colorectal cancer patients after first‐line biological agent treatment
Arıcı, S., Hamdard, J., Sakin, A., Erhan, S. Ş., Atçı, M. M., Çekin, R., Saka, B., Köse, E., Saydam, T., Geredeli, Ç., et al. (2020) · Colorectal Disease · doi:10.1111/codi.15389 · Cited by 3
Primary site and treatment impact in unresectable metastatic colorectal cancer
Krishnan, T., Wang, F., Karapetis, C. S., Roy, A. C., & Price, T. J. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2208353 · Cited by 3
Recommendations for the optimal management of peritoneal metastases in patients with colorectal cancer: a TTD and GECOP-SEOQ expert consensus statement
Grávalos, C., Pereira, F., Vera, R., Arjona‐Sánchez, Á., Losa, F., Ramos, I., Alfonso, P. G., Bayón, L. G., Cascales-Campos, P. A., & Aranda, E. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03204-7 · Cited by 4
Radioembolisation of liver metastases
Boshell, D., & Bester, L. (2023) · Journal of Medical Imaging and Radiation Oncology · doi:10.1111/1754-9485.13549 · Cited by 3
Differences in Colorectal Cancer Survival Based on Primary Tumor Location: Retrospective Study from a Single Institution
Díez‐Alonso, M., Mendoza‐Moreno, F., Ortega, M. A., Aguado, H., Matías, B., Vera, C., Soto, S., Quiroga, A., Blazquez, S. B., Álvarez‐Mon, M., et al. (2023) · Journal of Cancer · doi:10.7150/jca.85695 · Cited by 3
Sidedness-Dependent Prognostic Impact of Gene Alterations in Metastatic Colorectal Cancer in the Nationwide Cancer Genome Screening Project in Japan (SCRUM-Japan GI-SCREEN)
Kajiwara, T., Nishina, T., Yamashita, R., Nakamura, Y., Shiozawa, M., Yuki, S., Taniguchi, H., Hara, H., Ohta, T., Esaki, T., et al. (2023) · Cancers · doi:10.3390/cancers15215172 · Cited by 3
Toripalimab and Fruquintinib Therapy for Colorectal Cancer after Failed Multiline Chemotherapies: A Case Report
Kong, L.-Z., Zheng, Y., & Li, K. (2023) · Immunotherapy · doi:10.2217/imt-2023-0235 · Cited by 3
Expressions of CXCR3 and PD-1 on T cells and their clinical relevance in colorectal cancer
Wang, S., Zhang, Y., Chen, G., Zhao, P., Wang, X., Xu, B., & Yuan, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.111988 · Cited by 3
Gut Microbiome and colorectal cancer: discovery of bacterial changes with metagenomics application in Turkısh population
Ülger, Y., Delik, A., & Akkız, H. (2024) · Genes & Genomics · doi:10.1007/s13258-024-01538-2 · Cited by 6
Ramucirumab in second‑line advanced colorectal cancer therapy: A study on therapeutic outcomes and hepatic sinusoidal platelet aggregation
Kimura, K., Katata, Y., Umeda, Y., Tanaka, T., Yano, S., Yoshida, K., Fujiwara, T., Mori, Y., Yamada, T., & Nagasaka, T. (2024) · Oncology Letters · doi:10.3892/ol.2024.14572 · Cited by 3
Identification of beneficial populations for targeted-immunotherapy combinations: tailoring later-line care for patients with pMMR/MSS metastatic colorectal cancer
Li, D., Jin, H. Z., Liu, Y., Liu, J., Zhang, X., Wang, L., Fan, Z., Li, F., Zuo, J., Han, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1462346 · Cited by 3
Primary tumor sidedness is not prognostic factor in resectable colorectal cancer liver metastasis: a retrospective observational cohort study
Jo, S. J., Kim, J. M., Shin, J. K., Rhu, J., Huh, J. W., Choi, G., & Joh, J. (2024) · Annals of Surgical Treatment and Research · doi:10.4174/astr.2024.107.5.264 · Cited by 3
Primary tumour location, molecular alterations, treatments, and outcome in a population-based metastatic colorectal cancer cohort
Österlund, E., Hammarström, K., Nunes, L., Mathot, L., Mezheyeuski, A., Sjöblom, T., & Glimelius, B. L. G. (2025) · BJC Reports · doi:10.1038/s44276-025-00156-z · Cited by 3
Aktuelle Standards in der Diagnostik und Therapie des Kolonkarzinoms
Lordick, F., & Mössner, J. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-123913 · Cited by 3
Localization of the primary tumor of the colon: аre there essential differences?
Fedyanin, M. Y., Tryakin, A. A., & Tjulandin, S. A. (2017) · Surgery and Oncology · doi:10.17650/2220-3478-2017-7-3-35-48 · Cited by 3
Does the Different Locations of Colon Cancer Affect the Oncologic Outcome? A Propensity-Score Matched Analysis
Yang, K. M., Park, I. J., Lee, J. L., Yoon, Y. S., Kim, C. W., Lim, S., Kim, N. Y., Hong, S., Yu, C. S., & Kim, J. C. (2019) · Annals of Coloproctology · doi:10.3393/ac.2018.07.25 · Cited by 3
Therapeutische Relevanz molekularer Marker beim kolorektalen Karzinom
Nöpel‐Dünnebacke, S., Conradi, L., Reinacher‐Schick, A., & Ghadimi, M. B. (2020) · Der Onkologe · doi:10.1007/s00761-020-00777-8 · Cited by 3
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Vera, R., Salgado, M., Safont, M. J., Gallego-Plazas, J., González‐Flores, E., Élez, E., & Aranda, E. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02475-8 · Cited by 3
Efficacy of 90Y-Radioembolization in Metastatic Colorectal Cancer Depending on the Primary Tumor Side
Schindler, P., Masthoff, M., Harders, F., Schmidt, H., Stegger, L., Pascher, A., Rahbar, K., Wildgruber, M., & Köhler, M. (2020) · Digestive Diseases · doi:10.1159/000512744 · Cited by 3

Authors: Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V.
Affiliations: Universitair Ziekenhuis Leuven (BE)
Ludwig-Maximilians-Universität München (DE)
University of Campania "Luigi Vanvitelli" (IT)
Universitat Autònoma de Barcelona (ES)
Digestive Oncology, University Hospitals Leuven and KULeuven, Leuven, Belgium
Merck KGaA, Darmstadt (Germany) (DE)
University of Southern California (US)
Corresponding author: Tejpar, Sabine
ORCID: Tejpar, Sabine
Stintzing, Sebastian
Ciardiello, Fortunato
Tabernero, Josep
Beier, Frank
Esser, Regina
Lenz, Heinz-Josef
Heinemann, Volker
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2017-02-01
Volume: 3
Issue: 2
Pages: 194
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2016.3797
PMC: PMC7505121
OpenAlex: W2531319683
Cited by: 709
References: 24
Citations by year: 2026: 19 · 2025: 35 · 2024: 64 · 2023: 48 · 2022: 70 · 2021: 89 · 2020: 85 · 2019: 97 · 2018: 102 · 2017: 96
FWCI: 53.50
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
Funders: National Cancer Institute (P30CA014089)
Topics: Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
Keywords: metastatic colorectal cancer, RAS wild-type, primary tumor site, cetuximab, FOLFIRI, bevacizumab, first-line therapy, progression-free survival, overall survival, objective response rate, predictive biomarkers, CRYSTAL trial, FIRE-3 trial, EGFR inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks